Drug Trial Radar · NCT07285785
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Feb 11, 2026
Primary completion
Apr 20, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone. The main questions it aims to answer are: How does rifaximin 200 mg move through and leave the body in children with acute diarrhea? Is rifaximin safe for children in this age group? Does rifaximin plus ORT help resolve diarrhea faster than ORT alone? Researchers will compare rifaximin plus ORT to ORT alone to see if adding rifaximin improves outcomes. Participants will: Take one rifaximin 200 mg tablet + ORT three times a day for 3 days or receive ORT alone Receive oral rehydration therapy according to the investigator's standard of care Attend up to 4 clinic visits over 5 days and receive 4 follow-up phone calls Provide blood samples on Day 1 and Day 3 for pharmacokinetic testing (rifaximin group only) Provide stool samples to identify bacterial pathogens Keep a diary of stool frequency and consistency to help determine when diarrhea resolves Be monitored for side effects, vital signs, and laboratory changes
Conditions
- Diarrhea
- Gastroenteritis
- Bacterial Infection
- Acute Diarrhea
Interventions
Rifaximin 200 mg TabletDrug
Participants receive rifaximin 200 mg tablets orally three times daily (TID) for 3 days in combination with oral rehydration therapy (ORT). Blood samples for pharmacokinetic analysis are collected on Day 1 and Day 3 at pre-dose, 1 hour post-dose, and 6 to 8 hours post-dose.
Oral Rehydration Therapy (ORT)Other
Participants receive oral rehydration solution according to the investigator's standard of care. This is administered either alone (for the ORT-alone arm) or in combination with rifaximin (for the rifaximin + ORT arm). Participants or caregivers complete a daily diary documenting stool frequency, stool consistency, and related symptoms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Plasma Concentration (Cmax) of RifaximinTime frame: Days 1 and 3
- Time to Maximum Plasma Concentration (Tmax) of RifaximinTime frame: Days 1 and 3
- Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) for RifaximinTime frame: Days 1 and 3
- Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-τ) for RifaximinTime frame: Days 1 and 3
- Proportion of participants with Clinical CureTime frame: Up to Day 5 (End of Treatment)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Alliance Research Institute
Lynwood, California · Recruiting
Direct Helpers
Hialeah, Florida · Recruiting
SouthCoast Research Center
Miami, Florida · Recruiting
Oceane7 Medical & Research Center, Inc
Miami, Florida · Recruiting
Rophe Adult & Pediatric Medicine
Union City, Georgia · Recruiting
Innovative Clinical Research Center
Island Lake, Illinois · Recruiting
Cyn3rgy Research Corporation
Gresham, Oregon · Recruiting
Little Stars Pediatrics / Tattva Trials
Prosper, Texas · Recruiting
LinQ Research
Rosharon, Texas · Recruiting
Tekton Research
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.